FDA 483 - Bactolac Pharmaceutical, Inc. - June 25, 2015
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Bactolac Pharmaceutical, Inc., a dietary supplement contract manufacturer in Hauppauge, NY, revealed two significant observations. The firm failed to adequately investigate a product complaint involving metal fragments and did not extend the investigation to other potentially affected batches. Additionally, the company lacked proper quality control review and approval for in-house standard reference materials used in laboratory testing, specifically for botanical identity specifications.
ID · 63b4ee4a-6f2a-48ea-b009-1755b80158bf